Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
{{output}}
Background: In Italy, monoclonal antibodies targeting the CGRP pathway are subsidized for the preventive treatment of high frequency and chronic migraine (CM) in patients with a MIgraine Disability ASsessment (MIDAS) score ≥ 11.... ...
